June 2019 - Volume 3 - Issue - Contributor Index

Author:
Yaari, S.
Author:
Yablokova, V.

MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI®) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS): PS1457

Gisslinger, H.; Klade, C.; Georgiev, P.; More

HemaSphere. 3:670-671, June 2019.

Author:
Yachnakis, E.
Author:
Yacobovich, J.
Author:
Yacoub, A.

RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS: PF668

Pemmaraju, N.; Ali, H.; Gupta, V.; More

HemaSphere. 3:286-287, June 2019.

RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): PF672

Patnaik, M.; Ali, H.; Gupta, V.; More

HemaSphere. 3:289, June 2019.

Author:
Yacoup, A.
Author:
Yagasaki, H.
Author:
Yagci, M.
Author:
Yagci, N.
Author:
Yagi, H.

CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012): PS1263

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3:578, June 2019.

Author:
Yagüe, J.

INFECTIOUS COMPLICATIONS FOLLOWING ARI-0001 CELL (A3B1:CD8:4-1BB:CD3Z CART19) TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CD19+ RELAPSED / REFRACTORY MALIGNANCIES: PS1214

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Cardozo, C.; More

HemaSphere. 3:553-554, June 2019.

FRACTIONATED DOSING OF ARI-0001 CELLS (A3B1:CD8:4-1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES: S1636

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Caballero-Baños, M.; More

HemaSphere. 3:756, June 2019.

Author:
Yagurinoski, M.
Author:
Yahalom, V.
Author:
Yakoub-Agha, I.
Author:
Yakouben, K.

SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE: PS943

Dourthe, M. E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3:425, June 2019.

Author:
Yakushijin, Y.

LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA: PS1259

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3:575-576, June 2019.

Author:
Yamagata, K.
Author:
Yamagishi, M.
Author:
Yamaguchi, J.

MYELOMA-INDUCED MYELOID-DERIVED SUPPRESSOR CELLS ARE TARGETED BY IMMUNOMODULATORY DRUGS THAT REGULATE THE CCL5/CCR5 AXIS AND MIF AND IRF8 EXPRESSION: PS1354

Kuwahara-Ota, S.; Shimura, Y.; Isa, R.; More

HemaSphere. 3:619, June 2019.

Author:
Yamaguchi, K.
Author:
Yamakawa, T.
Author:
Yamamoto, C.

COMPARISON OF ALEMTUZUMAB, ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE GRAFT-VS-HOST DISEASE AND GRAFT-VS-LEUKEMIA EFFECT IN XENOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: PF784

Mashima, K.; Oh, I.; Fujiwara, K.; More

HemaSphere. 3:345-346, June 2019.

Author:
Yamamoto, K.

LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA: PS1259

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3:575-576, June 2019.

CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012): PS1263

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3:578, June 2019.

Author:
Yamamoto, M.
Author:
Yamamoto, S.

EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY: PF184

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3:44, June 2019.

Author:
Yamamoto, T.
Author:
Yamamura, J.
Author:
Yamane, T.
Author:
Yamasaki, R.

COMPARISON OF ALEMTUZUMAB, ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE GRAFT-VS-HOST DISEASE AND GRAFT-VS-LEUKEMIA EFFECT IN XENOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: PF784

Mashima, K.; Oh, I.; Fujiwara, K.; More

HemaSphere. 3:345-346, June 2019.

Author:
Yamashita, S.
Author:
Yan, D.
Author:
Yan, J. L.
Author:
Yan, L.
Author:
Yan, Y.

THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML: S833

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3:370, June 2019.

EMERGING CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL): S868

Bannerji, R.; Arnason, J.; Advani, R.; More

HemaSphere. 3:388-389, June 2019.

Author:
Yañez, L.

EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA. RETROSPECTIVE ANALYSIS IN OUR CENTER: PB2350

Romero, Gonzalez Y.; Mora, J.; Cortes, M. A.; More

HemaSphere. 3:1047, June 2019.

Author:
Yang, C.
Author:
Yang, C.-M.

INCIDENCE, CLINICAL FEATURES, RISK FACTORS AND OUTCOMES OF REFRACTORY ACQUIRED IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A CHINESE MULTI-CENTER EXPERIENCE: PF805

Gui, R.-Y.; Zhang, G.-C.; Wang, C.-C.; More

HemaSphere. 3:355, June 2019.

Author:
Yang, D. H.
Author:
Yang, D.-H.

A MULTICENTER, RETROSPECTIVE STUDY TO EVALUATE EFFICACY AND SAFETY OF BUSULFAN/FLUDARABINE CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: PS956

Lee, S.-S.; Jung, S.-H.; Heo, M. H.; More

HemaSphere. 3:430-431, June 2019.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION CAN ABROGATE INCREASING RISK OF RELAPSE FROM PERSISTENT MUTATIONS MEASURED BY TARGETED SEQUENCING AT REMISSION IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: S1613

Kim, T.; Ahn, J.-S.; Jung, S.-H.; More

HemaSphere. 3:743-744, June 2019.

Author:
Yang, F.
Author:
Yang, G.
Author:
Yang, H.
Author:
Yang, J.

FT-2102, AN IDH1 M INHIBITOR, COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS): RESULTS FROM A PHASE 1 STUDY: PF269

Cortes, J. E.; Watts, J.; Baer, M.; More

HemaSphere. 3:86-87, June 2019.

THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY: PF558

De Oca, Montes R.; Bhattacharya, S.; Vitali, N.; More

HemaSphere. 3:231, June 2019.

FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1051

De Botton, S.; Watts, J.; Baer, M.; More

HemaSphere. 3:475-476, June 2019.

EZH2 GAIN-OF-FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A PRELIMINARY ANALYSIS ON 590 PATIENTS: PS1247

Bödör, C.; Batlevi, C.; Nagy, N.; More

HemaSphere. 3:568-569, June 2019.

A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION: S1634

Palomba, M. L.; Batlevi, C.; Riviere, I.; More

HemaSphere. 3:755, June 2019.

Author:
Yang, L.
Author:
Yang, L.-H.

INCIDENCE, CLINICAL FEATURES, RISK FACTORS AND OUTCOMES OF REFRACTORY ACQUIRED IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A CHINESE MULTI-CENTER EXPERIENCE: PF805

Gui, R.-Y.; Zhang, G.-C.; Wang, C.-C.; More

HemaSphere. 3:355, June 2019.

Author:
Yang, M.
Author:
Yang, N.
Author:
Yang, S.
Author:
Yang, T.
Show: